FDF

Liraglutide Injection-- Type 2 diabetes

This is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STRENGTHS: 18 mg/3 mL

DOSAGE AND ADMINISTRATION: Initiate at 0.6 mg per day for one week. This dose is intended to reduce gastrointestinal symptoms during initial titration, and is not effective for glycemic control. After one week, increase the dose to 1.2 mg. If the 1.2 mg dose does not result in acceptable glycemic control, the dose can be increased to 1.8 mg.

Teriparatide Injection--Osteoporosis

This is a parathyroid hormone analog, (PTH 1-34), indicated for:

1)Treatment of postmenopausal women with osteoporosis at high risk for fracture.

2)Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture.

3)Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.

STRENGTHS: 0.6 mg/2.4 mL

DOSAGE AND ADMINISTRATION: Recommended dose is 20 mcg subcutaneously once a day. Use of the drug for more than 2 years during a patient’s lifetime is not recommended.

Desmopressin Injection-- Hemophilia A、von Willebrand’s Disease (Type I) and Diabetes Insipidus

This is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.

STRENGTHS: 4 mcg/mL, 15 mcg/mL

DOSAGE AND ADMINISTRATION: 

Hemophilia A: This is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. It will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. In certain clinical situations, it may be justified to try It in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored.

von Willebrand’s Disease (Type I): This is indicated for patients with mild to moderate classic von Willebrand s disease (Type I) with factor VIII levels greater than 5%. It will often maintain hemostasis in patients with mild to moderate von Willebrand's disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.

Diabetes Insipidus: This is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus.

Atosiban Injection—Premature delivery

This is a oxytocin receptor antagonist. It has the advantage of being more effective in suppressing contractions and having fewer side effects than other uterine inhibitors.

STRENGTHS: 6.75 mg/ 0.9 mL, 37.5 mg/5 mL

DOSAGE AND ADMINISTRATION: The intravenous injection was performed in three successive steps: an initial infusion of 6.75 mg with 7.5 mg/mL; Infusion was given immediately for 3 hours (0.3 mg/min), followed by another 45 hours (0.1 mg/min). A treatment should not last more than 48 hours. In one full course of treatment, the dose should not exceed 330mg.

Carbetocin—Uterine contraction weakly and Postpartum hemorrhage

This is a synthetic agonist of long acting oxytocin nine-peptide like that can be administered intravenously in a single dose immediately after an epidural or lumbar caesarean section to prevent -Uterinecontraction weakly and Postpartum hemorrhage.

STRENGTHS: 100 mcg/mL

DOSAGE AND ADMINISTRATION: A single dose of 100 micrograms (1 ml) is administered intravenously, slowly and in a single dose, within 1 minute after the baby has been delivered by caesarean section under epidural or lumbar anesthesia.

Liraglutide Injection--Obesity

This is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients.

STRENGTHS: 18 mg/3 mL

DOSAGE AND ADMINISTRATION: Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached.

Semaglutide Injection-- Type 2 diabetes

This is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STRENGTHS: 2 mg/1.5 mL

DOSAGE AND ADMINISTRATION: Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly.

Dulaglutide Injection-- Type 2 diabetes

This is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STRENGTHS: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL

DOSAGE AND ADMINISTRATION: Initiate at 0.75 mg subcutaneously once weekly. Dose can be increased to 1.5 mg once weekly for additional glycemic control.

Triptorelin--Prostate cancer

This is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer

STRENGTHS: 3.75 mg/branch, 11.25 mg/branch,22.5 mg/branch

DOSAGE AND ADMINISTRATION: This is administered by a single intramuscular injection in either buttock. Dosing schedule depends on the product strength selected: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, 22.5 mg every24 weeks.